AR
TGTX icon

Advisory Research’s TG Therapeutics TGTX Stock Holding History

Advisory Research’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-32,726
Closed -$876K – 350
2020
Q3 		$876K Buy
32,726
+12,920
+65% +$297K 0.09% 189
2020
Q2 		$386K Buy
+19,806
New +$319K 0.03% 265

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Advisory Research's TGTX Position: Q4 2020 in Review

Advisory Research sold out of TG Therapeutics (TGTX) in Q4 2020, closing a stake of 32,726 shares — an estimated $876K sold.

Advisory Research first reported a position in TGTX in Q2 2020 and held it in 2 quarters. The position peaked at $876K in Q3 2020. 247 funds tracked by Wall St. Rank hold TGTX as of Q4 2020.

  • Advisory Research reported no remaining TG Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Advisory Research sold 32,726 TG Therapeutics shares in Q4 2020, an estimated $876K.
  • Advisory Research first reported a position in TG Therapeutics in Q2 2020 and held it in 2 quarters.
  • Advisory Research's TG Therapeutics position peaked at $876K in Q3 2020.
  • 247 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2020.

Based on Advisory Research's 13F filing for Q4 2020, filed 12 Feb 2021.